Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(2):153–157. doi: 10.1111/j.1349-7006.2003.tb01412.x

Age‐dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: Lack of influence of carcinogen or testosterone treatment

Young‐Man Cho 1,✉, Satoru Takahashi 1, Makoto Asamoto 1, Shugo Suzuki 1, Shingo Inaguma 1, Naomi Hokaiwado 1, Tomoyuki Shirai 1
PMCID: PMC11160202  PMID: 12708490

Abstract

Sequential changes in the phenotype of prostatic lesions and the impact of additional carcinogen treatment or castration on development and progression of prostate cancers were examined in probasin/simian virus 40 (SV40) T antigen transgenic (TG) rats. Non‐invasive prostate adenocarcinomas were evident in all lobes at 15 weeks of age. Invasive tumors were limited to the anterior lobe at this time point and were found in all lobes in an age‐dependent manner thereafter. No metastasis was apparent at any age. Additional carcinogen treatment or castration did not enhance progression or generate selective growth of hormone‐independent prostate cancer cells. These results suggest that our TG rats are suitable for clarification of mechanisms in early stages of prostate carcinogenesis, that is, from prostatic intraepithelial neo‐plasia (PIN) to non‐invasive and then invasive lesions. (Cancer Sci 2003; 94: 153–157)

References

  • 1. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol 2002; 20: 3–9. [DOI] [PubMed] [Google Scholar]
  • 2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47. [DOI] [PubMed] [Google Scholar]
  • 3. Tominaga S. Cancer incidence in Japanese in Japan, Hawaii, and western United States. Natl Cancer Inst Monogr 1985; 69: 83–92. [PubMed] [Google Scholar]
  • 4. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001; 39: 219–26. [DOI] [PubMed] [Google Scholar]
  • 5. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocrinol Rev 1987; 8: 338–62. [DOI] [PubMed] [Google Scholar]
  • 6. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leupro‐lide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24. [DOI] [PubMed] [Google Scholar]
  • 7. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52–74. [DOI] [PubMed] [Google Scholar]
  • 8. Shirai T, Fukushima S, Ikawa E, Tagawa Y, Ito N. Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2'‐dimethyl‐4‐aminobiphenyl and ethinyl estradiol. Cancer Res 1986; 46: 6423–6. [PubMed] [Google Scholar]
  • 9. Ito N, Shirai T, Tagawa Y, Nakamura A, Fukushima S. Variation in tumor yield in the prostate and other target organs of the rat in response to varied dosage and duration of administration of 3,2'‐dimethyl‐4‐aminobiphenyl. Cancer Res 1988; 48: 4629–32. [PubMed] [Google Scholar]
  • 10. Shirai T, Sano M, Imaida K, Takahashi S, Mori T, Ito N. Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2'‐dimethyl‐4‐aminobiphenyl and development of androgen‐independent carcinomas after castration. Cancer Lett 1994; 83: 111–6. [DOI] [PubMed] [Google Scholar]
  • 11. Asamoto M, Hokaiwado N, Cho Y‐M, Takahashi S, Ikeda Y, Imaida K, Shirai T. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001; 61: 4693–700. [PubMed] [Google Scholar]
  • 12. Asamoto M, Hokaiwado N, Cho YM, Ikeda Y, Takahashi S, Shirai T. Metastasizing neuroblastomas from taste buds in rats transgenic for the simian virus 40 large T antigen under control of the probasin gene promoter. Toxicol Pathol 2001; 29: 363–8. [DOI] [PubMed] [Google Scholar]
  • 13. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998; 36: 59–63. [DOI] [PubMed] [Google Scholar]
  • 15. Sullivan CS, Pipas JM. T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol Mol Biol Rev 2002; 66: 179–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT. Down‐regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387–9. [PubMed] [Google Scholar]
  • 17. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57: 846–9. [PubMed] [Google Scholar]
  • 18. Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, Rinker‐Shaeffer CW, Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11307–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Duriez C, Falette N, Cortes U, Moyret‐Lalle C, Puisieux A. Absence of p53‐dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene 2000; 19: 2461–4. [DOI] [PubMed] [Google Scholar]
  • 20. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen‐independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687–91. [PubMed] [Google Scholar]
  • 21. Wiedenmann B, Kuhn C, Schwechheimer K, Waldherr R, Raue F, Brandeis WE, Kommerell B, Franke WW. Synaptophysin identified in metastases of neuroendocrine tumors by immunocytochemistry and immunoblotting. Am J Clin Pathol 1987; 88: 560–9. [DOI] [PubMed] [Google Scholar]
  • 22. Ermisch B, Schwechheimer K. Protein gene product (PGP) 9.5 in diagnostic (neuro‐) oncology. An immunomorphological study. Clin Neuropathol 1995; 14: 130–6. [PubMed] [Google Scholar]
  • 23. Isaacs W, Kainu T. Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 2001; 23: 36–41. [DOI] [PubMed] [Google Scholar]
  • 24. Stuart GR, Holcroft J, De Boer JG, Glickman BW Prostate mutations in rats induced by the suspected human carcinogen 2‐amino‐1‐methyl‐6‐phenylimi‐dazo[4,5‐b]pyridine. Cancer Res 2000; 60: 266–8. [PubMed] [Google Scholar]
  • 25. Masui T, Shirai T, Imaida K, Hirose M, Futakuchi M, Tatematsu M, Ito N. Ki‐ras mutations with frequent normal allele loss versus absence of p53 mutations in rat prostate and seminal vesicle carcinomas induced with 3,2'‐dimethyl‐4‐aminobiphenyl. Mol Carcinog 1995; 13: 21–6. [DOI] [PubMed] [Google Scholar]
  • 26. Condon MS, Kaplan LAE, Crivello JF, Horton L, Bosland MC. Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N‐methyl‐N‐nitrosourea and testosterone. Mol Carcinog 1999; 25: 179–86. [PubMed] [Google Scholar]
  • 27. Weber GF, Branson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002; 62: 2281–6. [PubMed] [Google Scholar]
  • 28. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, Ichikawa T. Location of KAI1 on the short arm of human chromosome 11and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32: 205–13. [DOI] [PubMed] [Google Scholar]
  • 29. Shirai T, Takahashi S, Mori T, Imaida K, Futakuchi M, Ye S‐H, Prins GS, Ito N. Immunohistochemically demonstrated androgen receptor expression in the rat prostate during carcinogenesis induced by 3,2'‐dimethyl‐4‐aminobi‐phenyl with or without testosterone. Urol Oncol 1995; 1: 263–8. [DOI] [PubMed] [Google Scholar]
  • 30. Takahashi S, Inaguma S, Sakakibara M, Cho YM, Suzuki S, Ikeda Y, Cui L, Shirai T. DNA methylation in the androgen receptor gene promoter in rat prostate cancers. Prostate 2002; 52: 82–8. [DOI] [PubMed] [Google Scholar]
  • 31. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164: 3–9. [PubMed] [Google Scholar]
  • 32. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88: 3009–14. [DOI] [PubMed] [Google Scholar]
  • 33. Prins GS, Sklarew RJ, Pertschuk LP. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998; 159: 641–9. [PubMed] [Google Scholar]
  • 34. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in an‐drogen‐refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687–97. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES